228 related articles for article (PubMed ID: 33191833)
41. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
42. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Venditti A; Piciocchi A; Candoni A; Melillo L; Calafiore V; Cairoli R; de Fabritiis P; Storti G; Salutari P; Lanza F; Martinelli G; Luppi M; Mazza P; Martelli MP; Cuneo A; Albano F; Fabbiano F; Tafuri A; Chierichini A; Tieghi A; Fracchiolla NS; Capelli D; Foà R; Alati C; La Sala E; Fazi P; Vignetti M; Maurillo L; Buccisano F; Del Principe MI; Irno-Consalvo M; Ottone T; Lavorgna S; Voso MT; Lo-Coco F; Arcese W; Amadori S
Blood; 2019 Sep; 134(12):935-945. PubMed ID: 31395600
[TBL] [Abstract][Full Text] [Related]
43. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.
Masetti R; Muratore E; Gori D; Prete A; Locatelli F
Ann Hematol; 2022 Nov; 101(11):2497-2506. PubMed ID: 36038660
[TBL] [Abstract][Full Text] [Related]
45. Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia.
Yucel OK; Alemdar MS; Atas U; Undar L
Chemotherapy; 2020; 65(5-6):166-170. PubMed ID: 33316797
[TBL] [Abstract][Full Text] [Related]
46. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
47. [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia].
Liu XJ; Huang XJ; Xu LP; Liu KY; Zhang XH; Yan CH; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):182-186. PubMed ID: 30929382
[No Abstract] [Full Text] [Related]
48. Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
Capria S; Trisolini SM; Diverio D; Minotti C; Breccia M; Cartoni C; Carmini D; Gozzer M; La Rocca U; Shafii Bafti M; Martelli M
Int J Hematol; 2022 Oct; 116(4):586-593. PubMed ID: 35551633
[TBL] [Abstract][Full Text] [Related]
49. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
50. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.
Grimm J; Jentzsch M; Bill M; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Blood Adv; 2020 Aug; 4(16):3864-3874. PubMed ID: 32810221
[TBL] [Abstract][Full Text] [Related]
52. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
53. Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience.
Panovska-Stavridis I; Pivkova-Veljanovska A; Ridova N; Stojanovski Z; Cadievski L; Trajkova S; Popova-Labacevska M; Matevska-Geshkovska N; Cevreska L; Georgievski B; Dimovski A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Dec; 41(3):5-12. PubMed ID: 33500364
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
Konuma T; Kondo T; Masuko M; Shimizu H; Shiratori S; Fukuda T; Kato J; Sawa M; Ozawa Y; Ota S; Uchida N; Kanda Y; Kako S; Fujisawa S; Fukushima K; Ichinohe T; Atsuta Y; Yanada M;
Bone Marrow Transplant; 2021 Nov; 56(11):2779-2787. PubMed ID: 34272486
[TBL] [Abstract][Full Text] [Related]
56. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
57. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
58. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
59. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
60. Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
Tian H; Chen GH; Xu Y; Ma X; Chen F; Yang Z; Jin ZM; Qiu HY; Sun AN; Wu DP
Leuk Lymphoma; 2015 May; 56(5):1353-61. PubMed ID: 25204372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
